European Archives - Page 536 of 1614 - European Medical Journal

Early CPAP Use May Lower Parkinson’s Risk in Sleep Apnoea

Obstructive sleep apnoea may increase the risk of developing Parkinson’s, but early treatment with continuous positive airway pressure therapy mitigates this risk.

Timing and Tumour Site Key in PSMA PET Assessment Post-Radiotherapy

New research highlights the significance of timing and tumour location when evaluating PSMA PET scans following radiotherapy in prostate cancer patients.

Neuroimaging Identifies Key Biomarkers of Friedreich Ataxia Progression in Childhood

The TRACK-FA study reveals that stalled spinal cord development in childhood Friedreich ataxia, offering new biomarkers for trials.

Type 2 Diabetes vs. Hypertension: Which Has a Greater Impact on Kidney Damage?

A recent study explored impact of hypertension and type 2 diabetes on kidney structure, revealing similar damage in both conditions.

Preoperative Allergy Delabelling: A Safe and Feasible Approach

The study also highlighted a reduction in restricted antibiotic use among patients in the intervention group compared with the control group.

Metabolic Imaging Enhances Liver Function Assessment Pre-Surgery

Discover a project that designed EchoNet-Liver, a deep-learning computer-vision pipeline to cirrhosis and steatotic liver disease.

Genetic Study Reveals 60 Key Genes Driving Congenital Heart Disease

Discover how 60 genes drive congenital heart disease. Learn how genetic testing improves outcomes.

Patient Perceptions Linked to Rheumatoid Arthritis Diagnosis Delays

A Danish study finds that symptom interpretation and beliefs about treatment impact how quickly patients with early rheumatoid arthritis seek medical help.

IL-33 Inhibition Shows Promise in High-Risk COPD

IL-33 inhibition with tozorakimab may offer clinical benefits in patients with COPD at high risk of exacerbations.

Ensitrelvir Significantly Reduces COVID-19 Transmission in Households

Ensitrelvir reduces risk of COVID-19 in household contacts when administered within 72 hours of symptom onset.